ReviewJournal of thoracic disease2017
Magmaris: a new generation metallic sirolimus-eluting fully bioresorbable scaffold: present status and future perspectives.
Review in Journal of thoracic disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 80 citations in OpenAlex.
- Biodegradable Metal-Based Stents: Advances, Challenges, and Prospects.Journal of functional biomaterials · 2025Review
- Bioresorbable scaffolds advances, challenges, and future directions.Annals of medicine and surgery (2012) · 2025Review
- Absorbable metal stents for vascular use in pediatric cardiology: progress and outlook.Frontiers in cardiovascular medicine · 2024Review
- Development and Future Trends of Protective Strategies for Magnesium Alloy Vascular Stents.Materials (Basel, Switzerland) · 2023Review
- Long-Term Temporospatial Complementary Relationship between Degradation and Bone Regeneration of Mg-Al Alloy.ACS applied bio materials · 2023Article
- Bioresorbable Magnesium-Based Stent: Real-World Clinical Experience and Feasibility of Follow-Up by Coronary Computed Tomography: A New Window to Look at New Scaffolds.Biomedicines · 2023Article
- Hierarchy of hybrid materials. Part-II: The place of organics-Frontiers in chemistry · 2023Review
- Bioresorbable vascular metallic scaffolds: Current status and research trends.Current opinion in biomedical engineering · 2022Article
- Improving the radiopacity of Fe-Mn biodegradable metals by magnetron-sputtered W-Fe-Mn-C coatings: Application for thinner stents.Bioactive materials · 2022Article
- Fabrication and evaluation of bioresorbable scaffolds for interventional cardiology application with sufficient drug release.Iranian journal of basic medical sciences · 2022Article
- Cardiovascular Stents: A Review of Past, Current, and Emerging Devices.Materials (Basel, Switzerland) · 2021Review
- High Magnesium and Sirolimus on Rabbit Vascular Cells-An In Vitro Proof of Concept.Materials (Basel, Switzerland) · 2021Article
- Biosafety and efficacy evaluation of a biodegradable magnesium-based drug-eluting stent in porcine coronary artery.Scientific reports · 2021Article
- Successful bailout stenting strategy against rare spontaneous retrograde dissection of partially absorbed magnesium-based resorbable scaffold: A case report.World journal of clinical cases · 2021Article
- Designing Better Cardiovascular Stent Materials - A Learning Curve.Advanced functional materials · 2021Article
- The Future of Paediatric Heart Interventions: Where Will We Be in 2030?Current cardiology reports · 2020Review
- Bioresorbable Scaffolds: Current Technology and Future Perspectives.Rambam Maimonides medical journal · 2020Review
- The Potential Impact and Timeline of Engineering on Congenital Interventions.Pediatric cardiology · 2020Review
- Bioresorbable Vascular Scaffolds-Dead End or Still a Rough Diamond?Journal of clinical medicine · 2019Review
- Understanding the Impact of Stent and Scaffold Material and Strut Design on Coronary Artery Thrombosis from the Basic and Clinical Points of View.Bioengineering (Basel, Switzerland) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-eluting stents (DES) have reached a high safety and efficacy profile, becoming the best option for percutaneous coronary interventions (PCI) based revascularization. However, despite their optimal performance, a few concerns remain regarding their use, mainly due to permanent caging of the vessels and its consequences, first of all late stent thrombosis (ST). Bioresorbable scaffolds (BRS) aim to overcome these issues. The results achieved in randomized controlled trials (RCT) by the first generation of poly-L-lactic acid (PLLA) based scaffolds were promising at 1 year, but the first long term reports (albeit flawed by non-optimal implantation technique) have been disappointing, showing, for instance, an increased risk of ST and target vessel myocardial infarction (TV-MI). In such a scenario the advent of a newer generation magnesium (Mg) based BRS is welcome, mainly because of its innovative mechanical and chemical features coupled with well proven biocompatibility. Despite being in its infancy, this technology seems to promise a great potential. In our article, we review the Magmaris (Biotronik AG, Bülach, Switzerland) Mg BRS development from animal models to human use, underscore its best qualities and weaknesses, and provide hints of its possible future perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.